These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19768418)

  • 1. Vaccines for pandemic influenza: summary of recent clinical trials.
    Keitel WA; Atmar RL
    Curr Top Microbiol Immunol; 2009; 333():431-51. PubMed ID: 19768418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.
    Luke CJ; Subbarao K
    Expert Rev Vaccines; 2014 Jul; 13(7):873-83. PubMed ID: 24855993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live attenuated vaccines for pandemic influenza.
    Chen GL; Subbarao K
    Curr Top Microbiol Immunol; 2009; 333():109-32. PubMed ID: 19768402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvants for pandemic influenza vaccines.
    Atmar RL; Keitel WA
    Curr Top Microbiol Immunol; 2009; 333():323-44. PubMed ID: 19768413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
    Suguitan AL; McAuliffe J; Mills KL; Jin H; Duke G; Lu B; Luke CJ; Murphy B; Swayne DE; Kemble G; Subbarao K
    PLoS Med; 2006 Sep; 3(9):e360. PubMed ID: 16968127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.
    Kreijtz JH; Osterhaus AD; Rimmelzwaan GF
    Hum Vaccin; 2009 Mar; 5(3):126-35. PubMed ID: 18948744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
    Crevar CJ; Carter DM; Lee KY; Ross TM
    Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for pandemic influenza.
    Luke CJ; Subbarao K
    Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic.
    Sambhara S; Poland GA
    Annu Rev Med; 2010; 61():187-98. PubMed ID: 20059335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.